With the end of the financial year fast approaching we have some rather large announcements that will hopefully be made.
Quoting straight from the BP report dated 21/04/17 the following announcements are predicted to be made prior to the EOFY2017:
• 4QFY17/1QFY18 – Top-line results from Phase I DEP docetaxel trial (dose escalation and expansion phase);
• 4QFY17 – NDA filing for VivaGel for Treament of Bacterial Vaginosis (BV) to US FDA for approval in US market;
• 4QFY17- Launch of VivaGel OTC (Over the counter) product for symptomatic relief of BV by Aspen in ANZ;
• 4QFY17 - Results from the two Phase III trials of VivaGel for Prevention of Recurrence of Bacterial Vaginosis;
• 4QFY17 - Licensing deal for VivaGel Treatment for BV for US market and the OTC product for BV for Ex-US markets with upfronts and milestones;
Lets hope that these announcements are made (on time) and that the market reacts positively and the SP rises accordingly.
SPL Price at posting:
74.0¢ Sentiment: Buy Disclosure: Held
